{"id":9748,"date":"2026-04-01T11:48:47","date_gmt":"2026-04-01T03:48:47","guid":{"rendered":"https:\/\/regask.com\/?p=9748"},"modified":"2026-04-01T15:51:32","modified_gmt":"2026-04-01T07:51:32","slug":"lagence-britannique-de-reglementation-des-medicaments-et-des-produits-de-sante-mhra-definit-un-cadre-reglementaire-pour-eliminer-progressivement-les-tests-sur-les-animaux-dans-le-developpement","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/","title":{"rendered":"L&#039;agence britannique de r\u00e9glementation des m\u00e9dicaments et des produits de sant\u00e9 (MHRA) d\u00e9finit une voie r\u00e9glementaire pour l&#039;\u00e9limination progressive des tests sur les animaux\u2026"},"content":{"rendered":"<p>Le 24 mars 2026, <strong>Agence de r\u00e9glementation des m\u00e9dicaments et des produits de sant\u00e9<\/strong> (MHRA) a introduit de nouveaux principes r\u00e9glementaires pour <strong>applications de commercialisation des m\u00e9dicaments \u00e0 usage humain<\/strong> qui d\u00e9pendent de <strong>Preuves non animales.<\/strong> Cette mise \u00e0 jour s&#039;inscrit dans la strat\u00e9gie globale du gouvernement britannique visant \u00e0 r\u00e9duire et \u00e0 remplacer les tests sur les animaux et s&#039;applique \u00e0 tous les m\u00e9dicaments en cours de d\u00e9veloppement. <strong>Autorisation de mise sur le march\u00e9 (AMM)<\/strong> au Royaume-Uni.<\/p>\n<div class=\"row\"  id=\"row-145092898\">\n\n\t<div id=\"col-675819304\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-94597120\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-94597120 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>D\u00e9tails de la mise \u00e0 jour<\/h2>\n\t<div id=\"gap-1741622297\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1741622297 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">La MHRA a \u00e9tabli\u00a0<\/span><b><span data-contrast=\"auto\">cinq principes r\u00e9glementaires<\/span><\/b><span data-contrast=\"auto\">\u00a0d\u00e9finir quand les tests sur les animaux sont obligatoires, facultatifs ou peuvent \u00eatre omis.\u00a0<\/span><b><span data-contrast=\"auto\">Produits g\u00e9n\u00e9riques, biosimilaires et pharmacologiquement inactifs<\/span><\/b><span data-contrast=\"auto\">\u00a0ne devrait pas \u00eatre soumis \u00e0 des tests sur les animaux, tandis que\u00a0<\/span><b><span data-contrast=\"auto\">tests de toxicit\u00e9 pour les produits biologiques<\/span><\/b><span data-contrast=\"auto\">\u00a0doit se limiter aux esp\u00e8ces pharmacologiquement pertinentes. L&#039;agence autorise \u00e9galement\u00a0<\/span><b><span data-contrast=\"auto\">produits dont les profils pharmacologiques sont bien connus<\/span><\/b><span data-contrast=\"auto\">\u00a0pour participer \u00e0 des essais cliniques au Royaume-Uni sans \u00e9tudes animales pr\u00e9alables. Cependant,\u00a0<\/span><b><span data-contrast=\"auto\">produits dot\u00e9s de nouveaux m\u00e9canismes pharmacologiques<\/span><\/b><span data-contrast=\"auto\">\u00a0doit toujours se conformer aux exigences internationales en mati\u00e8re d&#039;exp\u00e9rimentation animale. De plus,\u00a0<\/span><b><span data-contrast=\"auto\">vaccins contre les maladies infectieuses pand\u00e9miques \u00e9mergentes<\/span><\/b><span data-contrast=\"auto\">, lorsque l&#039;efficacit\u00e9 ne peut \u00eatre \u00e9valu\u00e9e lors d&#039;essais cliniques, doivent continuer \u00e0 s&#039;appuyer sur les tests sur les animaux.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Pour soutenir l&#039;adoption de\u00a0<\/span><b><span data-contrast=\"auto\">Nouvelles m\u00e9thodologies d&#039;approche (NAM)<\/span><\/b><span data-contrast=\"auto\">, y compris des mod\u00e8les d\u00e9riv\u00e9s de l&#039;humain et des analyses pilot\u00e9es par l&#039;IA, la MHRA introduira un\u00a0<\/span><b><span data-contrast=\"auto\">programme de r\u00e9vision anticip\u00e9e pour le module 4<\/span><\/b><span data-contrast=\"auto\">\u00a0d&#039;ici fin 2026. Cela permet aux entreprises d\u00e9veloppant des produits sans tests sur les animaux de soumettre\u00a0<\/span><b><span data-contrast=\"auto\">Module 4<\/span><\/b><span data-contrast=\"auto\">, le\u00a0<\/span><b><span data-contrast=\"auto\">Brochure de l&#039;enqu\u00eateur<\/span><\/b><span data-contrast=\"auto\">, et au moins un rapport d&#039;essai clinique pour une \u00e9valuation pr\u00e9liminaire. L&#039;agence fournira un\u00a0<\/span><b><span data-contrast=\"auto\">avis \u00e9crit non contraignant<\/span><\/b><span data-contrast=\"auto\">\u00a0sur l&#039;ad\u00e9quation des donn\u00e9es, qui peuvent \u00eatre incluses dans la demande finale d&#039;autorisation de mise sur le march\u00e9.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">La MHRA proc\u00e9dera \u00e0 un examen ult\u00e9rieur en consultation avec\u00a0<\/span><b><span data-contrast=\"auto\">Commission des m\u00e9dicaments \u00e0 usage humain<\/span><\/b><span data-contrast=\"auto\">, d\u00e9cidant en d\u00e9finitive d&#039;approuver ou de rejeter la demande, en fournissant les motifs de tout rejet. A\u00a0<\/span><b><span data-contrast=\"auto\">frais de recouvrement des co\u00fbts<\/span><\/b><span data-contrast=\"auto\">\u00a0Cette mesure s&#039;appliquera aux candidatures anticip\u00e9es afin de d\u00e9courager les candidatures inappropri\u00e9es, bien que le montant exact des frais n&#039;ait pas \u00e9t\u00e9 pr\u00e9cis\u00e9.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Il est important de noter que cette proc\u00e9dure d&#039;examen pr\u00e9alable s&#039;applique uniquement \u00e0\u00a0<\/span><b><span data-contrast=\"auto\">Demandes d&#039;autorisation de mise sur le march\u00e9<\/span><\/b><span data-contrast=\"auto\">\u00a0et n&#039;a pas d&#039;impact\u00a0<\/span><b><span data-contrast=\"auto\">Autorisation d&#039;essai clinique<\/span><\/b><span data-contrast=\"auto\">\u00a0proc\u00e9dures.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p>Cette initiative s&#039;inscrit dans la strat\u00e9gie du gouvernement britannique pour novembre 2025., <strong>\u201c Remplacer les animaux en science : une strat\u00e9gie pour soutenir le d\u00e9veloppement, la validation et l\u2019adoption de m\u00e9thodes alternatives. \u201d<\/strong> Cela renforce l&#039;\u00e9volution r\u00e9glementaire vers <strong>cadres d&#039;exp\u00e9rimentation sans animaux<\/strong> dans le d\u00e9veloppement de m\u00e9dicaments.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-675819304 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1093417422\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Chronologies<\/h2>\n\t<div id=\"gap-1934039285\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1934039285 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Le <strong>programme de r\u00e9vision du module 4 avanc\u00e9<\/strong> devrait devenir op\u00e9rationnel d&#039;ici le <strong>fin 2026. <\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1093417422 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-830328561\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Pourquoi c&#039;est important<\/h2>\n\t<div id=\"gap-1981652483\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1981652483 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Cette mise \u00e0 jour fournit <strong>orientations r\u00e9glementaires claires<\/strong> sur l&#039;utilisation de preuves non animales, permettant une plus grande<strong> certitude r\u00e9glementaire<\/strong> pour les entreprises pharmaceutiques et biotechnologiques. En formalisant les conditions permettant de r\u00e9duire ou d&#039;\u00e9viter les tests sur les animaux, la MHRA soutient <strong>innovation num\u00e9rique et scientifique<\/strong>, y compris les m\u00e9thodologies bas\u00e9es sur l&#039;IA. L&#039;introduction d&#039;un m\u00e9canisme d&#039;examen pr\u00e9alable pourrait am\u00e9liorer<strong> efficacit\u00e9 du d\u00e9veloppement<\/strong> et r\u00e9duire les risques li\u00e9s aux preuves, tout en maintenant la rigueur r\u00e9glementaire et en minimisant les charges inutiles.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-830328561 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-878798524\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Qui est concern\u00e9 ?<\/h2>\n\t<div id=\"gap-2057470767\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2057470767 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW120779043 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW120779043 BCX0\">Cette mise \u00e0 jour est pertinente pour\u00a0<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW120779043 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW120779043 BCX0\">\u00e9quipes des affaires r\u00e9glementaires, de la recherche et du d\u00e9veloppement, de l&#039;assurance qualit\u00e9 et des finances<\/span><\/span><\/strong><span class=\"TextRun SCXW120779043 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW120779043 BCX0\">\u00a0au sein des organisations pharmaceutiques et biotechnologiques, les parties prenantes doivent \u00e9valuer comment les nouveaux principes s&#039;appliquent \u00e0 leurs portefeuilles de produits.,\u00a0<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW120779043 BCX0\">en particulier pour<\/span><span class=\"NormalTextRun SCXW120779043 BCX0\">\u00a0<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW120779043 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW120779043 BCX0\">produits biologiques, g\u00e9n\u00e9riques, biosimilaires et th\u00e9rapies innovantes<\/span><\/span><\/strong><span class=\"TextRun SCXW120779043 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW120779043 BCX0\"><strong>,<\/strong> et garantir la conformit\u00e9 aux exigences de la MHRA.<\/span><\/span><span class=\"EOP SCXW120779043 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-878798524 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-761744642\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Prochaines \u00e9tapes<\/h2>\n\t<div id=\"gap-1984036212\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1984036212 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Les organisations doivent consulter l&#039;int\u00e9gralit\u00e9 des directives de la MHRA pour d\u00e9terminer comment\u00a0<\/span><b><span data-contrast=\"auto\">cinq principes r\u00e9glementaires<\/span><\/b><span data-contrast=\"auto\">\u00a0appliquer \u00e0 leurs produits et \u00e9valuer la valeur strat\u00e9gique de\u00a0<\/span><b><span data-contrast=\"auto\">sch\u00e9ma de soumission avanc\u00e9 du module 4<\/span><\/b><span data-contrast=\"auto\">\u00a0avant sa mise en \u0153uvre. Les \u00e9quipes doivent \u00e9galement \u00e9valuer la pertinence de\u00a0<\/span><b><span data-contrast=\"auto\">ensembles de donn\u00e9es non animales<\/span><\/b><span data-contrast=\"auto\">, aligner les plans d&#039;\u00e9tudes non cliniques sur le cadre actualis\u00e9 et tenir compte des risques potentiels\u00a0<\/span><b><span data-contrast=\"auto\">frais de recouvrement des co\u00fbts<\/span><\/b><span data-contrast=\"auto\">\u00a0dans la planification du d\u00e9veloppement.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">\u00c0 mesure que les attentes r\u00e9glementaires \u00e9voluent vers\u00a0<\/span><b><span data-contrast=\"auto\">m\u00e9thodologies sans animaux et preuves \u00e9tay\u00e9es par l&#039;IA<\/span><\/b><span data-contrast=\"auto\">, Il devient crucial d&#039;anticiper les changements mondiaux. RegASK est une plateforme de pointe d&#039;intelligence r\u00e9glementaire et d&#039;orchestration des flux de travail bas\u00e9e sur l&#039;IA agentique. Elle permet aux organisations internationales des secteurs fortement r\u00e9glement\u00e9s, tels que les produits de consommation et les sciences de la vie, de s&#039;orienter proactivement dans des environnements r\u00e9glementaires complexes. En combinant une IA agentique avanc\u00e9e et l&#039;expertise de sp\u00e9cialistes, <a href=\"http:\/\/regask.com\/fr\/\">RegASK<\/a> Elle fournit en temps opportun des informations pr\u00e9dictives exploitables et une automatisation de bout en bout, rationalisant les processus de conformit\u00e9, att\u00e9nuant les risques et acc\u00e9l\u00e9rant l&#039;acc\u00e8s au march\u00e9 dans plus de 160 pays. <strong><a href=\"http:\/\/regask.com\/fr\/\">En savoir plus<\/a> ou <a href=\"https:\/\/regask.com\/fr\/reserver-une-demo\/\">r\u00e9servez une d\u00e9mo maintenant.<\/a><\/strong><\/span><strong>\u00a0<\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-761744642 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-647699001\">\n\n\t<div id=\"col-86858421\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>FAQ<\/h3>\n\t<div id=\"gap-2098802144\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2098802144 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4><span class=\"TextRun MacChromeBold SCXW126598592 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW126598592 BCX0\">Que sont les nouvelles m\u00e9thodologies d&#039;approche (NAM) dans le d\u00e9veloppement de m\u00e9dicaments\u00a0?<\/span><\/span><span class=\"EOP SCXW126598592 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-386118641\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-386118641 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW29844584 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW29844584 BCX0\">Les NAM sont<strong>\u00a0<\/strong><\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW29844584 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW29844584 BCX0\">m\u00e9thodes scientifiques sans animaux<\/span><\/span><\/strong><span class=\"TextRun SCXW29844584 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW29844584 BCX0\"><strong>,<\/strong> notamment des mod\u00e8les cellulaires d\u00e9riv\u00e9s de l&#039;homme et des analyses pilot\u00e9es par l&#039;IA, utilis\u00e9s pour g\u00e9n\u00e9rer des preuves en vue du d\u00e9veloppement de m\u00e9dicaments.<\/span><\/span><span class=\"EOP SCXW29844584 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-86858421 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1022623383\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW128671175 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW128671175 BCX0\">Qu&#039;est-ce que le module 4 en marketing ?\u00a0<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW128671175 BCX0\">Autorisation<\/span><span class=\"NormalTextRun SCXW128671175 BCX0\">\u00a0application?<\/span><\/span><span class=\"EOP SCXW128671175 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-2113651516\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2113651516 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><strong><span class=\"TextRun MacChromeBold SCXW40790795 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW40790795 BCX0\">Module 4 <\/span><\/span><\/strong><span class=\"TextRun SCXW40790795 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW40790795 BCX0\">contient <\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW40790795 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW40790795 BCX0\">rapports d&#039;\u00e9tudes non cliniques<\/span><\/span><\/strong><span class=\"TextRun SCXW40790795 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW40790795 BCX0\"><strong>,<\/strong> y compris les donn\u00e9es pharmacologiques et toxicologiques, utilis\u00e9es pour \u00e9tayer l&#039;innocuit\u00e9 d&#039;un m\u00e9dicament.<\/span><\/span><span class=\"EOP SCXW40790795 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1022623383 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-151356695\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW106275594 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW106275594 BCX0\">Quand le programme d&#039;examen avanc\u00e9 du module 4 de la MHRA entrera-t-il en vigueur\u00a0?<\/span><\/span><span class=\"EOP SCXW106275594 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1918221234\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1918221234 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW170672751 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW170672751 BCX0\">Le dispositif devrait \u00eatre op\u00e9rationnel d&#039;ici le\u00a0<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW170672751 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW170672751 BCX0\">fin de\u00a0<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW170672751 BCX0\">2026<\/span><\/span><span class=\"TextRun SCXW170672751 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW170672751 BCX0\">.<\/span><\/span><span class=\"EOP SCXW170672751 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-151356695 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1210602162\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<p><span data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/fr\/\">RegASK<\/a>\u00a0aide les organisations\u00a0<\/span><b><span data-contrast=\"auto\">surveiller l&#039;\u00e9volution des exigences r\u00e9glementaires<\/span><\/b><span data-contrast=\"auto\">, \u00e9valuer\u00a0<\/span><b><span data-contrast=\"auto\">pr\u00e9paration des donn\u00e9es pour les soumissions sans recours aux animaux<\/span><\/b><span data-contrast=\"auto\">, et rationaliser\u00a0<\/span><b><span data-contrast=\"auto\">flux de travail de conformit\u00e9 de bout en bout<\/span><\/b><span data-contrast=\"auto\">, permettant une adoption plus efficace des NAM conform\u00e9ment aux attentes de la MHRA.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t<div id=\"gap-1699695451\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1699695451 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">RegASK aide les organisations\u00a0<\/span><b><span data-contrast=\"auto\">Suivre les changements r\u00e9glementaires, \u00e9valuer leur impact et coordonner les mises \u00e0 jour interfonctionnelles<\/span><\/b><span data-contrast=\"auto\">, permettant une conformit\u00e9 efficace aux exigences \u00e9volutives telles que\u00a0<\/span><b><span data-contrast=\"auto\">Mise \u00e0 jour des emballages, r\u00e9vision des notices d&#039;information et mise en \u0153uvre des notices num\u00e9riques<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1210602162 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>On March 24, 2026, the Medicines &amp; Healthcare products Regulatory Agency (MHRA) introduced new regulatory principles for human medicines marketing applications that rely on non-animal evidence. This update supports the UK Government\u2019s broader strategy to reduce and replace animal testing and applies to all medicines seeking Marketing Authorisation (MA) in the United Kingdom.<\/p>","protected":false},"author":41,"featured_media":9761,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33,526,35],"tags":[],"class_list":["post-9748","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-united-kingdom-regulations","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>UK MHRA Sets Regulatory Pathway for Drug Testing<\/title>\n<meta name=\"description\" content=\"UK MHRA sets a new regulatory pathway to phase out animal testing in drug development, promoting non-animal evidence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/lagence-britannique-de-reglementation-des-medicaments-et-des-produits-de-sante-mhra-definit-un-cadre-reglementaire-pour-eliminer-progressivement-les-tests-sur-les-animaux-dans-le-developpement\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UK MHRA Sets Regulatory Pathway to Phase Out Animal Testing in Drug Development\" \/>\n<meta property=\"og:description\" content=\"UK MHRA sets a new regulatory pathway to phase out animal testing in drug development, promoting non-animal evidence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/lagence-britannique-de-reglementation-des-medicaments-et-des-produits-de-sante-mhra-definit-un-cadre-reglementaire-pour-eliminer-progressivement-les-tests-sur-les-animaux-dans-le-developpement\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T03:48:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T07:51:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/04\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Shaffa Renaningtyas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaffa Renaningtyas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\\\/\"},\"author\":{\"name\":\"Shaffa Renaningtyas\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/b0e1938ef6f244f9f052a21f21cba1b6\"},\"headline\":\"UK MHRA Sets Regulatory Pathway to Phase Out Animal Tes&hellip;\",\"datePublished\":\"2026-04-01T03:48:47+00:00\",\"dateModified\":\"2026-04-01T07:51:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\\\/\"},\"wordCount\":933,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development.png\",\"articleSection\":[\"Regulatory News\",\"United Kingdom\",\"Pharma and Biotech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\\\/\",\"name\":\"UK MHRA Sets Regulatory Pathway for Drug Testing\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development.png\",\"datePublished\":\"2026-04-01T03:48:47+00:00\",\"dateModified\":\"2026-04-01T07:51:32+00:00\",\"description\":\"UK MHRA sets a new regulatory pathway to phase out animal testing in drug development, promoting non-animal evidence.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development.png\",\"width\":800,\"height\":600,\"caption\":\"Uk Mhra Sets Regulatory Pathway To Phase Out Animal Testing In Drug Development\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@RegASK\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/b0e1938ef6f244f9f052a21f21cba1b6\",\"name\":\"Shaffa Renaningtyas\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"L&#039;agence britannique de r\u00e9glementation des m\u00e9dicaments et des produits de sant\u00e9 (MHRA) d\u00e9finit un cadre r\u00e9glementaire pour les essais de m\u00e9dicaments.","description":"L&#039;agence britannique de r\u00e9glementation des m\u00e9dicaments et des produits de sant\u00e9 (MHRA) \u00e9tablit une nouvelle voie r\u00e9glementaire pour \u00e9liminer progressivement les tests sur les animaux dans le d\u00e9veloppement des m\u00e9dicaments, en promouvant les preuves autres que les animaux.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/lagence-britannique-de-reglementation-des-medicaments-et-des-produits-de-sante-mhra-definit-un-cadre-reglementaire-pour-eliminer-progressivement-les-tests-sur-les-animaux-dans-le-developpement\/","og_locale":"fr_FR","og_type":"article","og_title":"UK MHRA Sets Regulatory Pathway to Phase Out Animal Testing in Drug Development","og_description":"UK MHRA sets a new regulatory pathway to phase out animal testing in drug development, promoting non-animal evidence.","og_url":"https:\/\/regask.com\/fr\/lagence-britannique-de-reglementation-des-medicaments-et-des-produits-de-sante-mhra-definit-un-cadre-reglementaire-pour-eliminer-progressivement-les-tests-sur-les-animaux-dans-le-developpement\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-04-01T03:48:47+00:00","article_modified_time":"2026-04-01T07:51:32+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/04\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development.png","type":"image\/png"}],"author":"Shaffa Renaningtyas","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Shaffa Renaningtyas","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/#article","isPartOf":{"@id":"https:\/\/regask.com\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/"},"author":{"name":"Shaffa Renaningtyas","@id":"https:\/\/regask.com\/#\/schema\/person\/b0e1938ef6f244f9f052a21f21cba1b6"},"headline":"UK MHRA Sets Regulatory Pathway to Phase Out Animal Tes&hellip;","datePublished":"2026-04-01T03:48:47+00:00","dateModified":"2026-04-01T07:51:32+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/"},"wordCount":933,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/04\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development.png","articleSection":["Regulatory News","United Kingdom","Pharma and Biotech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/","url":"https:\/\/regask.com\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/","name":"L&#039;agence britannique de r\u00e9glementation des m\u00e9dicaments et des produits de sant\u00e9 (MHRA) d\u00e9finit un cadre r\u00e9glementaire pour les essais de m\u00e9dicaments.","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/04\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development.png","datePublished":"2026-04-01T03:48:47+00:00","dateModified":"2026-04-01T07:51:32+00:00","description":"L&#039;agence britannique de r\u00e9glementation des m\u00e9dicaments et des produits de sant\u00e9 (MHRA) \u00e9tablit une nouvelle voie r\u00e9glementaire pour \u00e9liminer progressivement les tests sur les animaux dans le d\u00e9veloppement des m\u00e9dicaments, en promouvant les preuves autres que les animaux.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/04\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/04\/uk-mhra-sets-regulatory-pathway-to-phase-out-animal-testing-in-drug-development.png","width":800,"height":600,"caption":"Uk Mhra Sets Regulatory Pathway To Phase Out Animal Testing In Drug Development"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Favoriser des d\u00e9cisions r\u00e9glementaires plus intelligentes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/@RegASK"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/b0e1938ef6f244f9f052a21f21cba1b6","name":"Shaffa Renaningtyas"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/9748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/41"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=9748"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/9748\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/9761"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=9748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=9748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=9748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}